Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 301–400 of 1,000
Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin
Rachner, T. D., Hofbauer, L. C., Göbel, A., & Tsourdi, E. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0173 · Cited by 49
McClung, M. R., Bolognese, M., Brown, J. P., Reginster, J., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., & Grauer, A. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05502-0 · Cited by 51
Self-citationStructural and functional insights into sclerostin-glycosaminoglycan interactions in bone
Salbach‐Hirsch, J., Samsonov, S. A., Hintze, V., Hofbauer, C., Picke, A., Rauner, M., Gehrcke, J.-P., Moeller, S. J., Schnabelrauch, M., Scharnweber, D., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.021 · Cited by 50
Management of fracture risk in CKD—traditional and novel approaches
Haarhaus, M. L., Aaltonen, L., Cejka, D., Cozzolino, M. G., de Jongh, R. T., D’Haese, P. C., Evenepoel, P., Lafage‐Proust, M., Mazzaferro, S., McCloskey, E. V., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac230 · Cited by 58
Yorgan, T. A., Peters, S., Jeschke, A., Benisch, P., Jakob, F., Amling, M., & Schinke, T. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2461 · Cited by 48
Sclerostin and Bone Aging: A Mini-Review
Haÿ, E., Bouaziz, W., Funck‐Brentano, T., & Cohen-Solal, M. E. (2016) · Gerontology · doi:10.1159/000446278 · Cited by 53
Efficacy of Osteoporosis Therapies in Diabetic Patients
Schwartz, A. V. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0177-8 · Cited by 54
Revisiting the links between bone remodelling and osteocytes: insights from across phyla
Currey, J. D., Dean, M. N., & Shahar, R. (2016) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12302 · Cited by 50
Bone loss in chronic kidney disease: Quantity or quality?
Zheng, C., Zheng, J.-Q., Wu, C., Lu, C., Shyu, J., Yung-Ho, H., Wu, M., Chiu, I., Wang, Y., Lin, Y., et al. (2016) · Bone · doi:10.1016/j.bone.2016.03.017 · Cited by 55
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
Toscani, D., Bolzoni, M., Ferretti, M., Palumbo, C., & Giuliani, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02467 · Cited by 50
The best of both worlds — managing the cancer, saving the bone
Makhoul, I., Montgomery, C. O., Gaddy, D., & Suva, L. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.185 · Cited by 53
Anorexia nervosa and bone metabolism
Fazeli, P. K., & Klibanski, A. (2014) · Bone · doi:10.1016/j.bone.2014.05.014 · Cited by 57
Suen, P. K., ZHU, T. Y., Chow, D. H. K., Huang, L., Zheng, L., & Qin, L. (2015) · Scientific Reports · doi:10.1038/srep15632 · Cited by 47
Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice
Funck-Brentano, T., Nilsson, K. H., Brommage, R., Henning, P., Lerner, U. H., Koskela, A., Tuukkanen, J., Cohen-Solal, M., Movérare-Skrtic, S., & Ohlsson, C. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0153 · Cited by 47
Romosozumab: A Novel Agent in the Treatment for Postmenopausal Osteoporosis
Miller, S. A., St. Onge, E. L., & Whalen, K. L. (2021) · Journal of Pharmacy Technology · doi:10.1177/8755122520967632 · Cited by 46
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
Lewiecki, E. M., Shah, A. D., & Shoback, D. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s73244 · Cited by 70
Chronic kidney disease and bone metabolism
Kazama, J. J., Matsuo, K., Iwasaki, Y., & Fukagawa, M. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0639-x · Cited by 57
Sclerostin, Osteocytes, and Chronic Kidney Disease – Mineral Bone Disorder
Moysés, R. M. A., & Schiavi, S. C. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12415 · Cited by 46
Sinder, B. P., Lloyd, W. R., Salemi, J. D., Marini, J. C., Caird, M. S., Morris, M. D., & Kozloff, K. M. (2016) · Bone · doi:10.1016/j.bone.2016.01.001 · Cited by 52
Impact of aging on bone, marrow and their interactions
Hoffman, C. M., Han, J., & Calvi, L. M. (2018) · Bone · doi:10.1016/j.bone.2018.07.012 · Cited by 49
Saito, T., Mizobuchi, M., Kato, T., Suzuki, T., Fujiwara, Y., Kanamori, N., MAKUUCHI, M., & Honda, H. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-01031-6 · Cited by 50
R-spondins: Novel matricellular regulators of the skeleton
Knight, M. N., & Hankenson, K. D. (2014) · Matrix Biology · doi:10.1016/j.matbio.2014.06.003 · Cited by 49
Paccou, J., Mentaverri, R., Renard, C., Liabeuf, S., Fardellone, P., Massy, Z. A., Brazier, M., & Kamel, S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2327 · Cited by 45
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0888-7 · Cited by 52
Kim, S., Kang, K., Kim, J. W., Lim, S., & Hahn, M. H. (2017) · Journal of Bone Metabolism · doi:10.11005/jbm.2017.24.1.65 · Cited by 48
Pflanz, D., Birkhold, A. I., Albiol, L., Thiele, T., Julien, C., Seliger, A., Thomson, E., Kramer, I., Kneissel, M., Duda, G. N., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09653-9 · Cited by 43
Extracellular vesicles in bone: “dogrobbers” in the “eternal battle field”
Tao, S., & Guo, S. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0319-5 · Cited by 48
Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment
Park, S. Y., Ahn, S. H., Yoo, J., Chung, Y., Jeon, Y. K., Yoon, B., Kim, H. Y., Lee, S. H., Lee, J., & Hong, S. (2019) · Journal of Bone Metabolism · doi:10.11005/jbm.2019.26.4.213 · Cited by 49
Gregson, C. L., Bergen, D. J. M., Leo, P., Sessions, R. B., Wheeler, L., Hartley, A., Youlten, S., Croucher, P. I., McInerney-Leo, A. M., Fraser, W., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3875 · Cited by 44
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
Ebina, K., Etani, Y., Noguchi, T., Nakata, K., & Okada, S. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01536-0 · Cited by 47
Conservative Treatments in the Management of Acute Painful Vertebral Compression Fractures
Alimy, A., Anastasilakis, A. D., CAREY, J. J., D’Oronzo, S., Naciu, A. M., Paccou, J., Yavropoulou, M. P., Lems, W. F., & Rolvien, T. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32041 · Cited by 45
Sinha, P. S., Aarnisalo, P., Chubb, R., Poulton, I. J., Guo, J., Nachtrab, G. T., Kimura, T., Swami, S., Saeed, H., Chen, M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679753 · Cited by 46
Wang, K., Le, L., Chun, B. M., Tiede-Lewis, L. M., Shiflett, L. A., Prideaux, M., Campos, R., Veno, P. A., Xie, Y., Dusevich, V., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3720 · Cited by 50
Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta
Cardinal, M., Tys, J., Roels, T., Lafont, S., Ominsky, M. S., Devogelaer, J., Chappard, D., Mabilleau, G., Ammann, P., Behets, C., et al. (2019) · Bone · doi:10.1016/j.bone.2019.04.011 · Cited by 45
Gupta, N., Kanwar, N., Arora, A., Khatri, K., & Kanwal, A. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-06932-5 · Cited by 52
Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis
Rauner, M., & Bözec, A. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01323-9 · Cited by 52
Integrated Therapies for Osteoporosis and Sarcopenia: From Signaling Pathways to Clinical Trials
Girgis, C. M. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9956-x · Cited by 44
Role of bone-anabolic agents in the treatment of breast cancer bone metastases
Suvannasankha, A., & Chirgwin, J. M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0484-9 · Cited by 44
LRP5: From bedside to bench to bone
Williams, B. O. (2017) · Bone · doi:10.1016/j.bone.2017.03.044 · Cited by 46
New agents in the Treatment of Myeloma Bone Disease
Ring, E. S., Lawson, M. A., Snowden, J. A., Jolley, I., & Chantry, A. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0351-7 · Cited by 47
Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease
Zeng, C., Guo, C., Cai, J., Tang, C., & Dong, Z. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117742316 · Cited by 43
Vitamin D–regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification
Nguyen‐Yamamoto, L., Tanaka, K., St‐Arnaud, R., & Goltzman, D. (2019) · JCI Insight · doi:10.1172/jci.insight.126467 · Cited by 44
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
Tonk, C. H., Shoushrah, S. H., Babczyk, P., Khaldi-Hansen, B. E., Schulze, M., Herten, M., & Tobiasch, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031393 · Cited by 49
Gregson, C. L., Wheeler, L., Hardcastle, S., Appleton, L., Addison, K., Brugmans, M., Clark, G. R., Ward, K. A., Paggiosi, M., Stone, M. D., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2706 · Cited by 42
Genetics of osteoporosis: searching for candidate genes for bone fragility
Rocha, M. G. M., & Ferraz‐de‐Souza, B. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000178 · Cited by 48
Polypharmacy in Osteoporosis Treatment
McConnell, M., & Shieh, A. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.05.011 · Cited by 42
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges
O'Brien, S., Chidiac, R., & Angers, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.03.008 · Cited by 39
Glorieux, F. H., Langdahl, B. L., Chapurlat, R. D., de Beur, S. M. J., Sutton, V. R., Poole, K. E. S., Dahir, K. M., ORWOLL, E. S., Willie, B. M., Mikolajewicz, N., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae112 · Cited by 45
Self-citationRecent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 49
Self-citationMECHANISMS IN ENDOCRINOLOGY: Genetics of human bone formation
Boudin, E., & Van Hul, W. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0990 · Cited by 40
Low-Density Lipoprotein Receptor-Related Proteins in Skeletal Development and Disease
Yang, T., & Williams, B. O. (2017) · Physiological Reviews · doi:10.1152/physrev.00013.2016 · Cited by 42
Role of bone-forming agents in the management of osteoporosis
McClung, M. R. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01708-8 · Cited by 46
Self-citationAnabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?
Cosman, F., & Dempster, D. W. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00663-1 · Cited by 43
Osteocyte specific responses to soluble and mechanical stimuli in a stem cell derived culture model
Thompson, W. R., Uzer, G., Brobst, K. E., Xie, Z., Sen, B., Yen, S. S., Styner, M., & Rubin, J. E. (2015) · Scientific Reports · doi:10.1038/srep11049 · Cited by 48
Management of adynamic bone disease in chronic kidney disease: A brief review
Sista, S. K., & Arum, S. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.07.002 · Cited by 42
The Pathophysiology of Osteoporosis after Spinal Cord Injury
Shams, R., Drasites, K. P., Zaman, V., Matzelle, D. D., Shields, D. C., Garner, D. P., Sole, C. J., Haque, A., & Banik, N. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063057 · Cited by 45
CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance
Zhao, G., Huang, B., Rigueur, D., Wang, W., Bhoot, C., Charles, K. R., Baek, J., Mohan, S., Jiang, J., & Lyons, K. M. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3394 · Cited by 43
Crosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives
Liu, Z., Liu, M., Xiong, Y., Wang, Y., & Bu, X. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13864 · Cited by 39
Kruck, B., Zimmermann, E. A., Damerow, S., Figge, C., Julien, C., Wulsten, D., Thiele, T., Martin, M., Hamdy, R. C., Reumann, M. K., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3454 · Cited by 48
Braun, L. T., Fazel, J., Zopp, S., Benedix, S., Osswald-Kopp, A., Riester, A., Rubinstein, G., Seidensticker, M., Beuschlein, F., Drey, M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4033 · Cited by 37
Qin, W., Li, X., Peng, Y., Harlow, L. M., Ren, Y., Wu, Y., Li, J., Qin, Y., Sun, J., Zheng, S., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2864 · Cited by 39
Androgens Inhibit the Osteogenic Response to Mechanical Loading in Adult Male Mice
Sinnesael, M., Laurent, M. R., Jardí, F., Dubois, V., Deboel, L., Delisser, P., Behets, G. J. S., D’Haese, P. C., Carmeliet, G., Claessens, F., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1673 · Cited by 39
Identification of novel osteogenic compounds by an ex-vivo sp7:luciferase zebrafish scale assay
de Vrieze, E., Zethof, J., Schulte‐Merker, S., Flik, G., & Metz, J. R. (2015) · Bone · doi:10.1016/j.bone.2015.01.006 · Cited by 40
Sinder, B. P., Zweifler, L. E., Koh, A. J., Michalski, M. N., Hofbauer, L. C., Aguirre, J. I., Roca, H., & McCauley, L. K. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3196 · Cited by 44
Li, X., Ominsky, M. S., Villasenor, K. S., Niu, Q., Asuncion, F., Xia, X., Grisanti, M. S., Wronski, T. J., Simonet, W. S., & Ke, H. Z. (2017) · Endocrinology · doi:10.1210/en.2017-00794 · Cited by 42
Sclerostin Inhibition for Osteoporosis — A New Approach
Becker, C. B. (2014) · New England Journal of Medicine · doi:10.1056/nejme1315500 · Cited by 38
Male Osteoporosis in the Elderly
D’Amelio, P., & Isaia, G. C. (2015) · International Journal of Endocrinology · doi:10.1155/2015/907689 · Cited by 41
Adverse Effects of Osteocytic Constitutive Activation of ß-Catenin on Bone Strength and Bone Growth
Chen, S., Feng, J., Bao, Q., Li, A., Zhang, B., Shen, Y., Zhao, Y., Guo, Q., Jing, J., Lin, S., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2453 · Cited by 40
New horizons in osteoporosis therapies
Harsløf, T., & Langdahl, B. L. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.012 · Cited by 39
Self-citationRNA-based therapy for osteogenesis
Wang, P., Perche, F., Logeart‐Avramoglou, D., & Pichon, C. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118594 · Cited by 38
Regulation of bone homeostasis by MERTK and TYRO3
Engelmann, J., Zarrer, J., Gensch, V., Riecken, K., Berenbrok, N., Luu, T. V., Beitzen‐Heineke, A., Vargas-Delgado, M. E., Pantel, K., Bokemeyer, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33938-x · Cited by 38
Sclerostin and skeletal health
Sharifi, M., Ereifej, L. K., & Lewiecki, E. M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9311-6 · Cited by 38
Imaging of Site Specific Bone Turnover in Osteoporosis Using Positron Emission Tomography
Blake, G. M., Siddique, M. M., Frost, M. L., Moore, A. E. B., & Fogelman, I. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0231-2 · Cited by 37
Pediatric Osteoporosis: Diagnosis and Treatment Considerations
Marrani, E., Giani, T., Simonini, G., & Cimaz, R. (2017) · Drugs · doi:10.1007/s40265-017-0715-3 · Cited by 38
Qin, W., Zhao, W., Li, X., Peng, Y., Harlow, L. M., Li, J., Qin, Y., Pan, J., Wu, Y., Ran, L., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3700-x · Cited by 36
Osteoporosis, densidad mineral ósea y complejo CKD-MBD (II): implicaciones terapéuticas
Bover, J., Ureña, P., Láiz, A. M., Torregrosa, J., Rodríguez-García, M., Castro-Alonso, C., Górriz, J. L., Benito, S., López‐Báez, V., Cora, M. J. L., et al. (2019) · Nefrología · doi:10.1016/j.nefro.2018.10.009 · Cited by 40
Genetic Approaches To Identifying Novel Osteoporosis Drug Targets
Brommage, R. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25179 · Cited by 36
Yavropoulou, M. P., Xygonakis, C., Lolou, M., Karadimou, F., & Yovos, J. G. (2014) · HORMONES · doi:10.14310/horm.2002.1552 · Cited by 42
Perosky, J. E., Khoury, B. M., Jenks, T. N., Ward, F. S., Cortright, K., Meyer, B., Barton, D. K., Sinder, B. P., Marini, J. C., Caird, M. S., et al. (2016) · Bone · doi:10.1016/j.bone.2016.09.013 · Cited by 35
Novel Therapies for Postmenopausal Osteoporosis
Bandeira, L., & Bilezikian, J. P. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.11.001 · Cited by 42
Takada, J., Dinavahi, R. V., Miyauchi, A., Hamaya, E., Hirama, T., Libanati, C. R., Nakamura, Y., Milmont, C. E., & Grauer, A. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01057-1 · Cited by 35
Self-citationRomosozumab: a novel bone anabolic treatment option for osteoporosis?
Kerschan‐Schindl, K. (2019) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-019-00721-5 · Cited by 40
Identification of osteogenic progenitor cell-targeted peptides that augment bone formation
Jiang, M., Liu, R., Liu, L., Kot, A., Liu, X., Xiao, W., Jia, J., Li, Y., Lam, K. S., & Yao, W. (2020) · Nature Communications · doi:10.1038/s41467-020-17417-9 · Cited by 37
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis
Prather, C., Adams, E. N., & Zentgraf, W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa285 · Cited by 39
Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020
Rolland, Y., Cesari, M., Fielding, R. A., Reginster, J., Vellas, B. J., & Cruz-Jentoft, A. J. (2021) · The Journal of Frailty & Aging · doi:10.14283/jfa.2021.4 · Cited by 37
Self-citationAdvances in bone turnover markers
Medio, L. D., & Brandi, M. L. (2021) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.06.001 · Cited by 45
The therapeutic potential of mesenchymal stem cells in treating osteoporosis
Chen, T., Yang, T., Zhang, W., & Shao, J. (2021) · Biological Research · doi:10.1186/s40659-021-00366-y · Cited by 39
A comprehensive study of long-term skeletal changes after spinal cord injury in adult rats
Lin, T., Tong, W., Chandra, A., Hsu, S.-Y., Jia, H., Zhu, J., Tseng, W., Levine, M. A., Zhang, Y., Yan, S.-G., et al. (2015) · Bone Research · doi:10.1038/boneres.2015.28 · Cited by 36
Hernández, A. V., Pérez-López, F. R., Piscoya, A., Pasupuleti, V., Roman, Y. M., Thota, P., & Herrera, A. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.08.003 · Cited by 36
Future directions for new medical entities in osteoporosis
Ferrari, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.002 · Cited by 34
Rolvien, T., Jandl, N. M., Stürznickel, J., Beil, F. T., Kötter, I., Oheim, R., Lohse, A. W., Barvencik, F., & Amling, M. (2020) · Calcified Tissue International · doi:10.1007/s00223-020-00765-5 · Cited by 34
Morse, A., Yu, N., Peacock, L., Mikulec, K., Krämer, I., Kneissel, M., McDonald, M. M., & Little, D. G. (2014) · Bone · doi:10.1016/j.bone.2014.10.018 · Cited by 36
Update on romosozumab: a humanized monoclonal antibody to sclerostin
Costa, A. G., Bilezikian, J. P., & Lewiecki, E. M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.895808 · Cited by 37
Pharmacological diversity among drugs that inhibit bone resorption
Russell, R. G. G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.005 · Cited by 41
New approaches to targeting the bone marrow microenvironment in multiple myeloma
Gooding, S., & Edwards, C. M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.013 · Cited by 37
Bhattacharyya, S., Pal, S., & Chattopadhyay, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.028 · Cited by 34
Li, K., Zhang, X., He, B., Yang, R., Zhang, Y., Shen, Z., Chen, P., & Du, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.040 · Cited by 34
Thyroid Hormone Actions and Bone Remodeling – The Role of the Wnt Signaling Pathway
Lademann, F., Tsourdi, E. A., Hofbauer, L. C., & Rauner, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1088-1215 · Cited by 36
Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23
Mäkitie, R. E., Kämpe, A. J., Costantini, A., Alm, J. J., Magnusson, P., & Mäkitie, O. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3959 · Cited by 35
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
Lim, S. Y. (2022) · Women s Health · doi:10.1177/17455057221125577 · Cited by 49
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.